Abdul Mannan: The Dual Biology of the Sickle Cell Mutation
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn about an article by Gavin Band et al. published in Nature, adding:
“The sickle mutation is not simply ‘protective’.
It depends on whether you inherit one copy or two.
That is the whole paradox.
Here’s the simple version:
- HbAS protects because the parasite creates local hypoxia inside the red cell
- That triggers limited HbS polymerisation
- The infected red cell sickles
- A working spleen clears it, parasite included
- Less PfEMP1 reaches the cell surface, so there is less adhesion and rosetting
But HbSS is different:
- The spleen is often lost early through repeated infarction
- Red cells are already under sickling stress
- There is no HbA buffer
- Baseline anaemia leaves little reserve
- Malaria then adds haemolysis on top of haemolysis
So the same mutation can act like a trap in HbAS, but becomes a liability in HbSS.
A 2022 Nature paper by Band et al. added another layer: HbS protection also depends on parasite genotype, with Pfsa1, Pfsa2 and Pfsa3 loci linked to parasites that can cause severe malaria despite HbS.
For trainees, this is a beautiful teaching point:
Genetics is never isolated from environment.
And malaria wrote part of the sickle cell story.
What is your favourite example of evolution shaping haematology?”
Title: Malaria protection due to sickle haemoglobin depends on parasite genotype
Authors: Gavin Band, Ellen M. Leffler, Muminatou Jallow, Fatoumatta Sisay-Joof, Carolyne M. Ndila, Alexander W. Macharia, Christina Hubbart, Anna E. Jeffreys, Kate Rowlands, Thuy Nguyen, Sónia Gonçalves, Cristina V. Ariani, Jim Stalker, Richard D. Pearson, Roberto Amato, Eleanor Drury, Giorgio Sirugo, Umberto d’Alessandro, Kalifa A. Bojang, Kevin Marsh, Norbert Peshu, Joseph W. Saelens, Mahamadou Diakité, Steve M. Taylor, David J. Conway, Thomas N. Williams, Kirk A. Rockett, Dominic P. Kwiatkowski

Other posts featuring Abdul Mannan on Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering